Use of reduced dose of OKT3 (2.5 mg) after renal transplantation

Transplant Proc. 2002 Feb;34(1):104. doi: 10.1016/s0041-1345(01)02688-4.
No abstract available

MeSH terms

  • Acute Disease
  • Dose-Response Relationship, Drug
  • Follow-Up Studies
  • Graft Rejection / drug therapy*
  • Humans
  • Kidney Transplantation / immunology*
  • Muromonab-CD3 / adverse effects
  • Muromonab-CD3 / therapeutic use*
  • Reoperation
  • Retrospective Studies
  • Tacrolimus / therapeutic use
  • Time Factors
  • Treatment Failure

Substances

  • Muromonab-CD3
  • Tacrolimus